论文部分内容阅读
胰腺癌患者血清GPDA活力变化尚乏完整报道。对166例消化道疾病及60例正常对照组血清GPDA测定结果表明,胰腺癌患者血清GPDA活力为101.02±75.84u/L(M±s),显著高于正常对照组。与胰腺炎差异显著(P<0.05)。胰腺癌患者血清GPDA活力增高集中于胰头癌,对胰头癌诊断敏感性为63.63％,并与肿瘤细胞分化程度有关,但是与肿瘤大小无关。此外,血清GPDA活力在胆管壶腹癌及肝癌患者中显著增高,在胃癌患者中显著降低。提示血清GPDA活力测定可作为胰腺癌及部份消化道肿瘤的辅助检查指标之一。
The changes of serum GPDA activity in patients with pancreatic cancer are still not fully reported. The results of serum GPDA in 166 patients with digestive tract diseases and 60 normal controls showed that the serum GPDA activity in patients with pancreatic cancer was 101.02±75.84u/L (M±s), which was significantly higher than that in the normal control group. There was a significant difference from pancreatitis (P<0.05). The increased serum GPDA activity in pancreatic cancer patients is mainly concentrated in the pancreatic head cancer. The sensitivity of the diagnosis of pancreatic head cancer is 63.63%, and is related to the degree of tumor cell differentiation, but not to the tumor size. In addition, serum GPDA activity was significantly increased in patients with bile duct ampullary carcinoma and hepatocellular carcinoma, and significantly decreased in gastric cancer patients. The serum GPDA activity assay can be used as one of the auxiliary indexes for pancreatic cancer and some digestive tract tumors.